Skip to main content
. 2013 Jul 5;8(7):e67754. doi: 10.1371/journal.pone.0067754

Table 1. Error percentages for 38 studies for the full ordinal scale (mRS 0.6), partially collapsed ordinal scale (mRS 0.3, 4–6) and dichotomization (mRS 0–1, 2–6; mRS 0–2, 3–6; mRS 0–3, 4–6; mRS 0–4, 5–6) and trichotomization (mRS 0–1, 2–4, 5–6; mRS 0–2, 3–4, 5–6) cut-points.

Study [Reference Number] mRS 0.6 mRS0.3, 4–6 mRS0–1, 2–6 mRS0–2, 3–6 mRS0–3, 4–6 mRS0–4, 5–6 mRS0–1, 2–4, 5–6 mRS0–2, 3–4, 5–6
ABESTT [36] 25.64 23.37 9.41 8.62 6.24 2.27 11.68 10.89
ABESTTII [37] 23.19 20.8 8.04 7.6 6.18 2.39 10.43 9.99
ABESTTIICo [37] 27.26 24.8 9.29 9.77 6.99 2.46 11.75 12.23
ABESTTIIW [37] 31.48 29.73 9.39 14.64 7.68 1.75 11.14 16.39
ARTIS [38] 31.92 30.07 11.07 12.88 8.2 1.85 12.92 14.73
CAIST [39] 26.7 25.22 11.71 8.73 5.84 1.48 13.19 10.21
CASTA-Cereb [40] 30.4 27.44 9.39 11.49 8.24 2.96 12.35 14.45
Camerlingo [41] 24.71 18.09 5.54 7.26 6.2 6.62 12.16 13.88
Cereb-rt-pa [42] 23.45 21.94 9.73 7.3 6.07 1.51 11.24 8.81
DECIMAL [3] 7.76 5.93 0 1.68 4.25 1.83 1.83 3.51
DESTINY [4] 18.98 15.19 0 8.17 7.02 3.79 3.79 11.96
DP-b99 [43] 25.84 20.41 4.87 7.75 9.07 5.43 10.3 13.18
DP-b99-MACSI [44] 27.15 23.23 7.67 8.9 7.52 3.92 11.59 12.82
ECASSII [45] 25.4 22.53 6.48 8.59 8.2 2.87 9.35 11.46
ECASSIII [46] 22.09 19.37 8.93 6.56 4.96 2.72 11.65 9.28
EPITHET [47] 27.83 23.9 7.85 9.1 8.16 3.93 11.78 13.03
EPO [48] 26.13 20.76 7.08 7.1 7.42 5.37 12.45 12.47
Edaravone [49] 29.37 26.69 13.2 9.22 6.16 2.68 15.88 11.9
Enlimomab [50] 24.61 21.55 7.02 8.75 6.91 3.06 10.08 11.81
FIST [51] 24.14 20.39 5.15 9.33 7.03 3.75 8.9 13.08
GAIN [52] 26.19 21.55 5.61 8.02 8.93 4.64 10.25 12.66
HAMLET [5] 16.99 15.62 1.79 7.43 7.18 1.37 3.16 8.8
ICTUS [53] 25.14 21.24 4.85 8.53 8.93 3.9 8.75 12.43
IMS-III [54] 25.54 22.49 7.35 9.26 6.9 3.05 10.4 12.31
INSULINFARCT [55] 29.59 27.27 8.66 11.46 9.11 2.32 10.98 13.78
IST-3 [22] 23.05 18.38 6.31 7.56 5.52 4.67 10.98 12.23
MELT [56] 32.31 25.52 7.45 10.83 8.58 6.79 14.24 17.62
MR-RESCUE-Pen [57] 32.33 26.17 4.45 11.1 11.22 6.16 10.61 17.26
MR-RES-Non-Pen [57] 25.97 17.26 1.89 6.44 9.28 8.71 10.6 15.15
Minocycline [58] 44.37 43.99 6.99 24.82 14.12 0.38 7.37 25.2
NEST-1 [59] 27.22 22.53 7.2 8.53 7.43 4.69 11.89 13.22
NEST-2 [60] 29.17 25.13 5.69 10.94 9.84 4.04 9.73 14.98
NINDS [61] 23.96 20.57 6.19 7.88 7.45 3.39 9.58 11.27
PROACTII [62] 24.09 20.31 2.85 8.89 9.16 3.78 6.63 12.67
SAINTI [20] 25.08 21.71 7.6 7.13 7.96 3.37 10.97 10.5
SAINTII [21] 26.24 22.5 7.3 9.02 7.26 3.74 11.04 12.76
Synthesis [63] 25.16 22.32 5.02 7.32 10.25 2.84 7.86 10.16
Synthesis Exp [64] 26.51 22.88 7.12 8.18 8.35 3.63 10.75 11.81